Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Francisco M. Marty(Brigham and Women's Hospital), Cyrus Badshah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yoshinobu Kanda(Jichi Medical University), Yuta Katayama(Karolinska University Hospital), Nicholas A. Kartsonis(Merck & Co., Inc., Rahway, NJ, USA (United States)), David R. Snydman(Tufts Medical Center), Kathleen M. Mullane(Karolinska University Hospital), Emily A. Blumberg(University of Pennsylvania), Valerie Teal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Boeckh(Fred Hutch Cancer Center), Sanjeet Dadwal(City Of Hope National Medical Center), Janice Brown(Karolinska University Hospital), Mark J. DiNubile(Io Therapeutics (United States)), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Yoshihiko Murata(University of Tsukuba Hospital), Rafael F. Duarte(Institut Català d'Oncologia), Hong Wan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Per Ljungman(Karolinska University Hospital), Johan Maertens(Unknown), Hermann Einsele(Karolinska University Hospital), Andrew J. Ullmann(University of Würzburg), Shariq Haider(Karolinska University Hospital), Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States))
New England Journal of Medicine
December 6, 2017
Cited by 1,203


Related Papers